Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
about
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Temozolomide Plus Bevacizumab ...... ANOCEF Phase II Trial (ATAG).
@en
Temozolomide Plus Bevacizumab ...... atus: An ANOCEF Phase II Trial
@nl
type
label
Temozolomide Plus Bevacizumab ...... ANOCEF Phase II Trial (ATAG).
@en
Temozolomide Plus Bevacizumab ...... atus: An ANOCEF Phase II Trial
@nl
prefLabel
Temozolomide Plus Bevacizumab ...... ANOCEF Phase II Trial (ATAG).
@en
Temozolomide Plus Bevacizumab ...... atus: An ANOCEF Phase II Trial
@nl
P2093
P2860
P50
P1433
P1476
Temozolomide Plus Bevacizumab ...... ANOCEF Phase II Trial (ATAG).
@en
P2093
Chantal Campello
Didier Frappaz
François Ghiringhelli
Germán Reyes-Botero
Isabelle Catry-Thomas
Isabelle Tennevet
Jean-Sebastien Guillamo
Jean-Yves Delattre
Jérôme Barrière
Jérôme Honnorat
P2860
P304
P356
10.1634/THEONCOLOGIST.2017-0689
P577
2018-02-22T00:00:00Z